Around the world, people suffer from a genetic condition called hemophilia. Even with expensive and time-consuming treatments, simple injuries for these patients hold the threat of turning into serious complications and even life-threatening events. But now, one biotech company has stumbled upon what very early trials suggest could be a "cure" -- something that, with a single intravenous drip, essentially corrects the genetic mutation that causes the disorder. This week, Bloomberg's Doni Bloomfield visits the scientists behind this treatment and a patient who has actually tried it. If it works, researchers may have pushed the door open to a whole new world of treatments that tackle these diseases at their source: our DNA.

<p>Around the world, people suffer from a genetic condition called hemophilia. Even with expensive and time-consuming treatments, simple injuries for these patients hold the threat of turning into serious complications and even life-threatening events. But now, one biotech company has stumbled upon what very early trials suggest could be a "cure" -- something that, with a single intravenous drip, essentially corrects the genetic mutation that causes the disorder. This week, Bloomberg's Doni Bloomfield visits the scientists behind this treatment and a patient who has actually tried it. If it works, researchers may have pushed the door open to a whole new world of treatments that tackle these diseases at their source: our DNA.</p>

Foundering is an award-winning, serialized podcast from the journalists at Bloomberg Technology. Each season, Foundering brings you inside a different high-stakes drama from the technology industry, where its companies are wielding unprecedented capital and power.

Foundering

Here's the Incredible Promise of Medicine That Targets Our DNA

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/fc6e6357-e7e0-4c28-833b-ae2b001e325f/transcript

Advertisement